Rainer Blair Lines Up 71,963 Danaher Shares For A Planned $16.9 Million Sale
Fidelity Brokerage Services would handle the proposed transaction, which covers shares from restricted-stock vesting and an option grant.
Rainer Blair plans to sell $16.9 million in shares of Danaher, which supplies instruments, consumables, software and services for biotechnology, life sciences and diagnostics. The proposed transaction covers 71,963 shares, according to a notice of a planned sale filed with the SEC Monday.
Fidelity Would Handle The Sale
Blair listed Fidelity Brokerage Services as the broker and Monday as the approximate sale date. The $16.9 million is the notice's aggregate market value for the shares, rather than proceeds from a completed sale.
The stock comes from restricted-stock vesting on February 2, 2026, received as compensation, and an option grant dated Monday with payment in cash.
A Modest Gain Since Year-End
DHR shares had gained 0.6% this year through Friday's close. Over the past 12 months through Friday's close, the gain was about 9%, placing Blair's proposed sale against a larger advance over that longer period.
Danaher's biotechnology business supplies drug-development and manufacturing equipment and consumables through brands including Cytiva and Pall. Its life-sciences operations sell research instruments, including microscopes and mass spectrometers, while its diagnostics business supplies testing tools used by hospitals, physicians' offices and reference laboratories.
The company has more than 15 operating businesses and facilities in approximately 50 countries. The United States accounted for 41% of sales in 2025.
Blair's notice records an intended sale; it does not establish that the shares have been sold.
Sources
- Form 144 — Rainer Blair (DHR) — SEC EDGAR